Safety and Efficacy of KM1 in Subjects With Recurrent or Refractory Ovarian Cancer

NCT05684731 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer

Interventions

BIOLOGICAL: KM1
DRUG: Chemotherapy

Sponsor

Tongji Hospital

Collaborators

[object Object]
[object Object]
[object Object]